Disclosed are compounds of general formula (I) such as 4-methoxy-5&rsquo&rsquo-methyl-6&rsquo-[5-(prop-1-yn-1-yl)pyridin-3-yl]-3&rsquoH-dispiro-[cyclohexane-1,2&rsquo-indene-1&rsquo,2&rsquo&rsquo-imidazol]-4&rsquo&rsquo-amine and its analogues, wherein: A is -O- or -CH2- n is 0 or 1 R1 is alkyl or haloalkyl R2 is hydrogen, alkylaryl, alkylheteroaryl, alkynyl, alkenyl, alkyl, halogen, cyano, haloalkyl, NHC(O)R9 or OR8 R5 and R6 are independently hydrogen, heterocyclyl, cycloalkyl, aryl, heteroaryl or alkyl, or R5 and R6 25 together with the carbon to which they are attached, form a ring B, which is a 3-14 membered cycloalkyl or heterocyclyl monocyclic ring, or a 9-14 membered bicyclic cycloalkyl or heterocyclyl ring. Representative compounds include 4-methoxy-5&rsquo&rsquo-methyl-6&rsquo-[5-(prop-1-yn-1-yl)pyridin-3-yl]-3&rsquoH-dispiro-[cyclohexane-1,2&rsquo-indene-1&rsquo,2&rsquo&rsquo-imidazol]-4&rsquo&rsquo-amine, 3-[4&rsquo&rsquo-amino-4-methoxy-5&rsquo&rsquo-methyl-3&rsquoH-dispiro[cyclohexane-1,2&rsquo-indene-1&rsquo,2&rsquo&rsquo-imidazol]-6&rsquo-yl]-5-chlorobenzonitrile, 4-methoxy-5&rsquo&rsquo-methyl-6&rsquo-(2-methylpropoxy)-3&rsquoH-dispiro[cyclohexane-1,2&rsquo-indene-1&rsquo,2&rsquo&rsquo-imidazol]-4&rsquo&rsquo-amine, N-(4&rsquo-amino-5&rsquo-methyl-spiro[chromane-4,2&rsquo-imidazole]-6-yl)-5-(trifluoromethyl)pyridine-2-carboxamide, 5-(4&rsquo&rsquo-amino-4-methoxy-5&rsquo&rsquo-methyl-3&rsquoH-dispiro[cyclohexane-1,2&rsquo-indene-1&rsquo,2&rsquo&rsquo-imidazol]-6&rsquo-yl)benzene-1,3-dicarbonitrile, 6&rsquo-(3-chlorophenyl)-5-methyl-2&rsquo&rsquo,3&rsquo&rsquo,5&rsquo&rsquo,6&rsquo&rsquo-tetrahydro-3&rsquoH-dispiro[imidazole-2,1&rsquo-indene-2&rsquo,4&rsquo&rsquo-pyran]-4-amine and 5&rsquo-bromo-4-methoxy-5&rsquo&rsquo-methyldispiro[cyclohexane-1,2&rsquo-[1]benzofuran-3&rsquo,2&rsquo&rsquo-imidazol]-4&rsquo&rsquo-amine. Also disclosed is a pharmaceutical composition comprising as active ingredient a therapeutically effective amount of a compound as d
